Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective.
Viceconti M, Tome M, Dartee W, Knezevic I, Hernandez Penna S, Mazzà C, Caulfield B, Garcia-Aymerich J, Becker C, Maetzler W, Troosters T, Sharrack B, Davico G, Corriol-Rohou S, Rochester L; Mobilise-D Consortium. Viceconti M, et al. Among authors: tome m. Front Med (Lausanne). 2022 Sep 21;9:996903. doi: 10.3389/fmed.2022.996903. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36213641 Free PMC article.
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.
Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K; Critical Path for Parkinson’s Consortium. Stephenson D, et al. Among authors: tome m. J Parkinsons Dis. 2019;9(3):553-563. doi: 10.3233/JPD-191648. J Parkinsons Dis. 2019. PMID: 31306141 Free PMC article.
The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.
Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, Conrado DJ, Dexter DT, Seibyl J, Jennings D, Nicholas T, Matthews D, Xie Z, Imam S, Maguire P, Russell D, Gordon MF, Stebbins GT, Somer E, Gallagher J, Roach A, Basseches P, Grosset D, Marek K; Critical Path for Parkinson’s Consortium. Stephenson D, et al. Among authors: tome m. J Parkinsons Dis. 2019;9(4):825. doi: 10.3233/JPD-199003. J Parkinsons Dis. 2019. PMID: 31524182 Free PMC article. No abstract available.
Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials.
Gold M, Amatniek J, Carrillo MC, Cedarbaum JM, Hendrix JA, Miller BB, Robillard JM, Rice JJ, Soares H, Tome MB, Tarnanas I, Vargas G, Bain LJ, Czaja SJ. Gold M, et al. Among authors: tome mb. Alzheimers Dement (N Y). 2018 May 24;4:234-242. doi: 10.1016/j.trci.2018.04.003. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 29955666 Free PMC article. Review.
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable.
Knopman DS, Haeberlein SB, Carrillo MC, Hendrix JA, Kerchner G, Margolin R, Maruff P, Miller DS, Tong G, Tome MB, Murray ME, Nelson PT, Sano M, Mattsson N, Sultzer DL, Montine TJ, Jack CR Jr, Kolb H, Petersen RC, Vemuri P, Canniere MZ, Schneider JA, Resnick SM, Romano G, van Harten AC, Wolk DA, Bain LJ, Siemers E. Knopman DS, et al. Among authors: tome mb. Alzheimers Dement. 2018 Apr;14(4):563-575. doi: 10.1016/j.jalz.2018.03.002. Alzheimers Dement. 2018. PMID: 29653607 Free PMC article. Review.
New approaches in psychiatric drug development.
van der Doef TF, Zaragoza Domingo S, Jacobs GE, Drevets WC, Marston HM, Nathan PJ, Tome MB, Tamminga CA, van Gerven JMA, Kas MJH. van der Doef TF, et al. Among authors: tome mb. Eur Neuropsychopharmacol. 2018 Sep;28(9):983-993. doi: 10.1016/j.euroneuro.2018.06.006. Epub 2018 Jul 25. Eur Neuropsychopharmacol. 2018. PMID: 30056086 Review.
286 results